Ziv-aflibercept (Zaltrap)
Also known as VEGF trap. When used for its approved macular degeneration indication, it is known as Eylea. in clinical trials
General information
Class/mechanism: fusion protein that binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PLGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, aflibercept is hypothesized to interfere with tumor angiogenesis.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
- Aflibercept patient drug information (UpToDate) -- note: this is for Eylea, not Zaltrap[2]